Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy;Eficacia y tolerabilidad del levetiracetam en 43 niños y adolescentes con epilepsia

Revista de Neurologia

Volumn 37, Issue 11, 2003, Pages 1005-1008

  Herranz, J L ^a   Rufo Campos, M ^b   Arteaga, R ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antiepileptic drugs; Children; Epilepsy; Levetiracetam; Partial seizures

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; IRRITABILITY; MALE; SIDE EFFECT; SOCIAL BEHAVIOR; SOMNOLENCE;

EID: 0347753309     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3711.2003423     Document Type: Article

References (22)

1. Herranz JL, Argumosa A. Características e indicaciones del levetiracetam. Rev Neurol 2002; 35 (Supl 1): S110-6.
2. ++ current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2001; 306: 5-8.
3. Rigo JM, Nguyen L, Belachew S, Mulgrange B, Leprince P, Moonen G, et al. Levetiracetam: novel modulation of ionotropic inhibitory receptors. Epilepsia 2000; 41 (Suppl 7): S35.
4. Madeja M, Margineanu DG, Klitgaard H. Effect of levetiracetam on voltage-gated potassium channels: a novel antiepileptic mechanism of action? Epilepsia 2001; 42 (Suppl 2): S19.
5. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
6. Perucca E, Gidal BE, Baltès E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003; 53: 47-56.
7. Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 2003; 44: 171-8.
8. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
9. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-86.
10. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3,000 mg/day in patients with refractory partial onset seizures: a multicenter double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276-83.
11. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000 mg daily and 4,000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-7.
12. Sharief MK, Singh P, Sander JW, Patsalos PN, Shorvon SD. Efficacy and tolerability study of UCB L059 in patients with refractory epilepsy. J Epilepsy 1996; 9: 106-12.
13. Grant R, Shorvon SD. Efficacy and tolerability of 1,000-4,000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 2000; 42: 89-95.
14. Wheless JW, Ng Y. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002; 17: 413-5.
15. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43: 518-24.
16. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003; 7: 123-8.
17. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1,000 and 3,000 mg day in adult patients with refractory epilepsy. Seizure 2003; 12: 141-9.
18. Veendrick-Meekes M, Renier WO, Lambrechts D. Levetiracetam therapy in children and adolescents with intractable epilepsy. Epilepsia 2002; 43 (Suppl 8): S37.
19. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. Dev Behav Pediatr 2002; 23: 225-30.
20. Cramer JA, Arrigo C, Van Hammee G, Gauer LJ, Cereghino JJ, for the N132 Study Group. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868-74.
21. Cramer JA, Van Hammee G, N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy & Behavior 2003; 4: 118-23.
22. Herranz JL. Levetiracetam en niños y adolescentes con epilepsia. Rev Neurol 2003; 37: 558-60.